USPTO Examiner FARRAR LAUREN PENG - Art Unit 3783

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19207572FLUID MEASURING RESERVOIR FOR BREAST PUMPSMay 2025August 2025Allow310YesNo
19031780DOSAGE MANAGEMENT AND PATIENT EDUCATION USING AN INTELLIGENT INJECTION DEVICEJanuary 2025December 2025Allow1111YesNo
18752035Gravity-Fed Burette SystemJune 2024April 2025Allow1010YesNo
18638167EPISTAXIS CONTROLLING DEVICE AND METHOD OF USING THE SAMEApril 2024February 2025Allow1011NoNo
18607862ASPIRATION MEDICAL DEVICEMarch 2024July 2025Allow1610NoNo
18605302AutoinjectorMarch 2024November 2025Allow2010NoNo
18601899Intravenous Catheter Insertion Device and Method of UseMarch 2024March 2025Allow1210NoNo
18581629Flush Syringe With Flip CapFebruary 2024January 2025Allow1110NoNo
18433332INJECTION DEVICES AND METHODS FOR MAKING AND USING THEMFebruary 2024March 2026Allow2510NoNo
18394510TREATMENT OF NEUROMUSCULAR DYSFUNCTIONDecember 2023June 2024Allow510YesNo
18543869Substance Delivery ApparatusDecember 2023June 2025Abandon1810NoNo
18542545FORMULATIONS AND METHODS FOR DIRECT SODIUM REMOVAL IN PATIENTS HAVING HEART FAILURE AND/OR SEVERE RENAL DYSFUNCTIONDecember 2023August 2025Allow2020NoNo
18524681INSERTERNovember 2023September 2025Allow2220NoNo
18524986Injection DeviceNovember 2023July 2025Allow1920YesNo
18515771SYSTEM AND METHOD FOR ULTRASOUND-ENHANCED DELIVERY OF DRUGSNovember 2023December 2025Allow2430YesNo
18514784AUTO INJECTOR WITH RECONSTITUTION HANDLING SUPPORTNovember 2023September 2025Allow2210NoNo
18500055DEVICE FOR DELIVERING AN ANTIMICROBIAL COMPOSITION INTO A MEDICAL DEVICENovember 2023May 2025Allow1910YesNo
18484101STABILIZATION DEVICES FOR USE WITH LOW-PROFILE FEEDING DEVICES AND RELATED METHODS OF USING THE SAMEOctober 2023May 2025Abandon1910NoNo
18473439ROBOTIC PERCUTANEOUS DEVICE WIPERSeptember 2023February 2025Allow1710NoNo
18238796FLOW METER HAVING A VALVEAugust 2023October 2025Allow2620NoNo
18348855MEDICAL CONNECTORJuly 2023November 2025Allow2810NoNo
18218884AutoinjectorJuly 2023February 2024Allow710YesNo
18215934Methods and Devices for Paranasal Sinus Drug DeliveryJune 2023October 2025Allow2820YesNo
18211799SUCTION AND IRRIGATION DEVICEJune 2023April 2025Allow2110YesNo
18195191DRUG DELIVERY SYSTEM WITH MULTIPOLAR MAGNET AND SENSOR SYSTEMMay 2023October 2025Allow2920NoNo
18309919SENSOR DEVICE FOR ATTACHMENT TO AN INJECTION DEVICEMay 2023February 2026Allow3330YesNo
18131502INJECTION DEVICEApril 2023April 2025Allow2510NoNo
18115131PHARMACEUTICAL CONTAINER AND LIQUID COMPOSITIONFebruary 2023September 2025Allow3121NoNo
18112265FRONT LOADED AUTO INJECTOR FOR ADMINISTERING A MEDICAMENTFebruary 2023March 2025Allow2510NoNo
18157741FORMULATIONS AND METHODS FOR DIRECT SODIUM REMOVAL IN PATIENTS HAVING HEART FAILURE AND/OR SEVERE RENAL DYSFUNCTIONJanuary 2023August 2023Allow710NoNo
18016184SYSTEM AND METHOD FOR INFORMATION MANAGEMENT IN COMPUTERIZED INJECTORSJanuary 2023March 2026Allow3810YesNo
18084167Medicament Delivery DeviceDecember 2022June 2025Allow3020NoNo
18061287INTRABODY SURGICAL FLUID TRANSFER ASSEMBLIES WITH ADJUSTABLE EXPOSED CANNULA TO NEEDLE TIP LENGTH, RELATED SYSTEMS AND METHODSDecember 2022May 2025Allow2911NoNo
18061385DEVICE FOR DELIVERING AN ANTIMICROBIAL COMPOSITION INTO A MEDICAL DEVICEDecember 2022December 2025Allow3630YesNo
17980094THERAPEUTIC APPLICATIONS OF ARTIFICIAL CEREBROSPINAL FLUID AND TOOLS PROVIDED THEREFORNovember 2022March 2025Abandon2910NoNo
17974212DIGITAL MICROFLUIDIC DELIVERY DEVICEOctober 2022October 2024Allow2310NoNo
17969409DELIVERY DEVICEOctober 2022September 2024Allow2310NoNo
17918812INJECTION SYRINGEOctober 2022January 2026Allow3910NoNo
17962785DIRECT STREAM HYDRODYNAMIC CATHETER SYSTEMOctober 2022June 2025Allow3230YesNo
17938418IMPLANTABLE PUMP FOR DIRECT SODIUM REMOVAL THERAPY HAVING ON-BOARD ANALYTE SENSOROctober 2022January 2026Allow3910NoNo
17938161Hazardous Agent Injection SystemOctober 2022March 2025Allow2920NoNo
17933427Electroporation Device and Injection ApparatusSeptember 2022February 2025Abandon2910NoNo
17823388MEDICATION INFUSION COMPONENTS AND SYSTEMSAugust 2022September 2024Allow2510NoNo
17823393MEDICATION INFUSION COMPONENTS AND SYSTEMSAugust 2022October 2025Abandon3820YesNo
17798959AN INJECTION DEVICE WITH INTEGRATED NEEDLESAugust 2022July 2025Abandon3510NoNo
17760164PROTECTED STERILE INJECTOR WITH READY ISOTONICAugust 2022January 2026Abandon4110NoNo
17876869RFID TAG ENABLED NEEDLE SHIELDJuly 2022October 2025Allow3810NoNo
17860514Method for Bubble-Free Gas-Enrichment of a Flowing Liquid within a ConduitJuly 2022September 2024Allow2610NoNo
17843908MEDICAL DEVICE WITH ANTIMICROBIAL PROPERTIESJune 2022September 2024Allow2710NoNo
17837461Adaptor and Drug Delivery DeviceJune 2022July 2025Allow3710NoNo
17835663DEVICE CONTAINERJune 2022October 2025Allow4010NoNo
17831974ELECTRONICS FOR DOSAGE SENSINGJune 2022December 2024Allow3010YesNo
17826508Hub Component for Vented ConnectorMay 2022March 2025Allow3320YesNo
17741314AUTO INJECTOR WITH TEMPERATURE CONTROLMay 2022February 2025Allow3320NoNo
17661907MEDICAL DELIVERY DEVICE WITH LAMINATED STOPPERMay 2022May 2024Allow2510NoNo
17661735MEDICAL DELIVERY DEVICE WITH LAMINATED STOPPERMay 2022May 2024Allow2410NoNo
17726381AutoinjectorApril 2022April 2024Allow2400NoNo
17724177REPORTING SYRINGEApril 2022January 2026Allow4540YesNo
17635146PEN-LIKE SYRINGE SYSTEMFebruary 2022November 2025Allow4510YesNo
17670700CAP ASSEMBLY FOR A MEDICAMENT DELIVERY DEVICEFebruary 2022May 2024Allow2710NoNo
17634680Medicament Container with Electronic IdentifierFebruary 2022August 2025Abandon4210NoNo
17592360INTERCHANGEABLE FLUSH/SELECTIVE CATHETERFebruary 2022June 2024Allow2910NoNo
17646009TRANSDERMAL PATCH PROVIDING IMPROVED PERMEABILITY AND COMPOSITIONDecember 2021October 2024Allow3331YesNo
17558839SYSTEMS, APPARATUSES AND METHODS TO ENCOURAGE INJECTION SITE ROTATION AND PREVENT LIPODYSTROPHY FROM REPEATED INJECTIONS TO A BODY AREADecember 2021February 2023Allow1420YesNo
17556153METHOD AND APPARATUS FOR INJECTING A NEUROTOXIN INTO A LOCALIZED AREADecember 2021September 2024Abandon3310NoNo
17536954INJECTION DEVICE WITH CAMMED RAM ASSEMBLYNovember 2021August 2024Allow3320NoNo
17531231Oral Product Delivery DeviceNovember 2021November 2025Allow4830YesNo
17529150AUTO INJECTOR WITH DETECTION OF USED CARTRIDGE AND ASSOCIATED METHODNovember 2021January 2024Allow2610NoNo
17450887Supplementary Device for a Manually Operable Injection DeviceOctober 2021May 2025Allow4310NoNo
17500529Apparatus and System for Diabetes ManagementOctober 2021August 2025Abandon4610NoNo
17499612MEDICATION INFUSION COMPONENTS AND SYSTEMSOctober 2021June 2024Allow3220YesNo
17496536FEED-FORTIFY ENTERAL FEEDING AND RELATED METHODS THEREFOROctober 2021February 2024Allow2810NoNo
17495962SYRINGE APPARATUS FOR DISINFECTION OF CENTRAL LINE PORT NEEDLELESS CONNECTOR AND METHOD OF DISINFECTING A CENTRAL LINE PORT NEEDLELESS CONNECTOROctober 2021April 2024Abandon3010NoNo
17468558DRUG DELIVERY DEVICESeptember 2021November 2023Allow2710NoNo
17464749INFUSION DEVICE WITH STABILIZER MEMBERSeptember 2021May 2024Allow3320NoNo
17400985SYSTEMS AND METHODS FOR POSITIONING FLUID SUPPLY SYSTEMAugust 2021May 2025Abandon4540NoNo
17386770Flush Syringe With Flip CapJuly 2021October 2023Allow2720NoNo
17425513NEEDLELESS INJECTION DEVICEJuly 2021October 2025Allow5130NoNo
17362665NEEDLELESS INJECTORS AND RELATED METHODSJune 2021December 2024Allow4210NoNo
17359825WEARABLE INJECTOR WITH STERILE ADHESIVE PATCHJune 2021August 2024Allow3820YesNo
17244262MICRO-NEEDLE ARRAY UNITApril 2021January 2025Abandon4520NoNo
17243402SYRINGES AND MEDICAL DEVICES WITH WINDOWED LABELSApril 2021October 2023Allow2930YesNo
17301855GUIDE CATHETER CONTROL FLEXIBLE TRACKApril 2021December 2023Allow3220NoNo
17224975PROTECTIVE MEMBRANE FOR MEDICAL LUER CONNECTORSApril 2021March 2026Allow5940NoNo
17283318INTEGRATED MULTI-MEDICATION TREATMENT DELIVERY SYSTEMApril 2021March 2025Abandon4720YesNo
17281769DELIVERY DEVICEMarch 2021June 2022Allow1430NoNo
17218298SYRINGE APPARATUS FOR DISINFECTION OF CENTRAL LINE PORT NEEDLELESS CONNECTOR AND METHOD OF DISINFECTING A CENTRAL LINE PORT NEEDLELESS CONNECTORMarch 2021September 2021Allow510NoNo
17213777SYSTEMS, COMPONENTS, AND COMBINATIONS THEREOF FOR PEN-TYPE INJECTION DEVICESMarch 2021February 2025Allow4731NoNo
17214471IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAMEMarch 2021January 2024Allow3420YesNo
17213115AutoinjectorMarch 2021November 2025Allow5620YesNo
17195825Medical Fluid Cassette Leak Detection Methods And DevicesMarch 2021June 2025Allow5110NoNo
17193395PHARMACEUTICAL PACKAGING RECEPTACLE WITH A LUBRICANT LAYER FOR REMOVAL OF A CHARGEMarch 2021December 2023Allow3310NoNo
17187435SUCTION AND IRRIGATION DEVICEFebruary 2021April 2023Allow2610NoNo
17182431STABILIZATION DEVICES FOR USE WITH LOW-PROFILE FEEDING DEVICES AND RELATED METHODS OF USING THE SAMEFebruary 2021August 2023Allow3020YesNo
17172211Sensor Assembly and System, Method, and Computer Program Product for Identifying Devices Connected to Device ConnectorsFebruary 2021February 2026Allow6050NoNo
17173011CANNULATION TIME TRACKINGFebruary 2021November 2023Allow3320NoNo
17168862DETECTION AND COMMUNICATION OF PLUNGER POSITION USING INDUCTIONFebruary 2021February 2023Allow2510NoNo
17168784TUBULAR INSTRUMENT TO REDUCE VEIN TRAUMA AND RELATED DEVICES AND METHODSFebruary 2021February 2025Allow4860YesNo
17167805MULTIPURPOSE CAPACITIVE SENSOR FOR FLUID PUMPSFebruary 2021February 2025Allow4810NoNo
17265352OCCLUSION CATHETER SYSTEM FOR FULL OR PARTIAL OCCLUSIONFebruary 2021April 2024Allow3820YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FARRAR, LAUREN PENG.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
12
Examiner Affirmed
6
(50.0%)
Examiner Reversed
6
(50.0%)
Reversal Percentile
79.4%
Higher than average

What This Means

With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
31
Allowed After Appeal Filing
10
(32.3%)
Not Allowed After Appeal Filing
21
(67.7%)
Filing Benefit Percentile
49.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 32.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner FARRAR, LAUREN PENG - Prosecution Strategy Guide

Executive Summary

Examiner FARRAR, LAUREN PENG works in Art Unit 3783 and has examined 405 patent applications in our dataset. With an allowance rate of 82.5%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner FARRAR, LAUREN PENG's allowance rate of 82.5% places them in the 55% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by FARRAR, LAUREN PENG receive 2.44 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by FARRAR, LAUREN PENG is 35 months. This places the examiner in the 41% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +9.9% benefit to allowance rate for applications examined by FARRAR, LAUREN PENG. This interview benefit is in the 43% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 26.3% of applications are subsequently allowed. This success rate is in the 43% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 35.6% of cases where such amendments are filed. This entry rate is in the 53% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 57.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 49% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 68.4% of appeals filed. This is in the 54% percentile among all examiners. Of these withdrawals, 38.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 51.4% are granted (fully or in part). This grant rate is in the 51% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 46% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 49% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

    Relevant MPEP Sections for Prosecution Strategy

    • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
    • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
    • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
    • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
    • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
    • MPEP § 1214.07: Reopening prosecution after appeal

    Important Disclaimer

    Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

    No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

    Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

    Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.